# SkinBioTherapeutics Plc Significant progress and on track

- Link: https://www.directorstalkinterviews.com/skinbiotherapeutics-plc-significant-progress-track/412746115
- Published: 2018-02-21T07:16:02+00:00
- Author: Giles Arbor

**SkinBioTherapeutics plc** (LON: SBTX) a life sciences company focused on skin 
health, has today announced its half year results for the six months to 31 December
2017.

**Key highlights**

· Significant progress in developing the SkinBiotix® technology; successful initial
lysate manufacture scale-up

· Three different formulation options for the cosmetic application are being assessed
ahead of the [human study](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)
scheduled in Q3 2018

· Anti-infection and eczema programmes progressing – application frequency and safe
dosing levels determined

· Early stage commercial discussions with significant industry players continuing
with respect to the cosmetic application

· Cash as at period end at £3.6m (2016: £0.4m)

> **Dr. Cath O’Neill, CEO of SkinBioTherapeutics Plc, said:** “We have made significant
> progress in the past six months around our SkinBiotix® technology and we are on
> track with the advancement of all three indications in cosmetics, anti-infection
> and eczema.
> “Our primary focus has been on developing the cosmetic application. Manufacturing
> scale-up and formulation is progressing to plan. As laid out at IPO, we intend
> to carry out the human safety study later this year.
> “There is a growing awareness of our SkinBiotix® platform technology from the 
> skin healthcare industry, based on the reputation of our team and our ‘science-
> led’ business approach. With continued work on our technology and the start of
> human studies in Q3, we are building further value for shareholders and a strong
> position from which to hold potential commercial discussions.”

Share on: